PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Carlos Eduardo dos Santos Ferreira [verfasserIn] Francisco Antônio Helfenstein Fonseca [verfasserIn] Cristóvão Luis Pitangueira Mangueira [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Portugiesisch |
| Erschienen: |
São Paulo, Vol 10, Iss 4, Pp 526-527 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017, (São Paulo, Vol 10, Iss 4, Pp 526-527) |
|---|---|
| Übergeordnetes Werk: |
year:São Paulo, Vol 10, Iss 4, Pp 526-527 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.1590/S1679-45082012000400024 |
|---|
| Katalog-ID: |
DOAJ002336081 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ002336081 | ||
| 003 | DE-627 | ||
| 005 | 20230309170109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/S1679-45082012000400024 |2 doi | |
| 035 | |a (DE-627)DOAJ002336081 | ||
| 035 | |a (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 100 | 0 | |a Carlos Eduardo dos Santos Ferreira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| 264 | 1 | |c São Paulo, Vol 10, Iss 4, Pp 526-527 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. | ||
| 650 | 4 | |a dislipidemias | |
| 650 | 4 | |a lipoproteínas | |
| 650 | 4 | |a ldl-colesterol | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Francisco Antônio Helfenstein Fonseca |e verfasserin |4 aut | |
| 700 | 0 | |a Cristóvão Luis Pitangueira Mangueira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Einstein (São Paulo) |d Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 |g (São Paulo, Vol 10, Iss 4, Pp 526-527) |w (DE-627)561316503 |w (DE-600)2418293-X |x 23176385 |7 nnns |
| 773 | 1 | 8 | |g year:São Paulo, Vol 10, Iss 4, Pp 526-527 |
| 856 | 4 | 0 | |u https://doi.org/10.1590/S1679-45082012000400024 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1679-4508 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2317-6385 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j São Paulo, Vol 10, Iss 4, Pp 526-527 | ||
| author_variant |
c e d s f cedsf f a h f fahf c l p m clpm |
|---|---|
| matchkey_str |
article:23176385:--------::ckadtciiaipracwtteeteaetcagt |
| hierarchy_sort_str |
São Paulo, Vol 10, Iss 4, Pp 526-527 |
| allfields |
10.1590/S1679-45082012000400024 doi (DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 DE-627 ger DE-627 rakwb eng por Carlos Eduardo dos Santos Ferreira verfasserin aut PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia São Paulo, Vol 10, Iss 4, Pp 526-527 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. dislipidemias lipoproteínas ldl-colesterol Medicine R Francisco Antônio Helfenstein Fonseca verfasserin aut Cristóvão Luis Pitangueira Mangueira verfasserin aut In Einstein (São Paulo) Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 (São Paulo, Vol 10, Iss 4, Pp 526-527) (DE-627)561316503 (DE-600)2418293-X 23176385 nnns year:São Paulo, Vol 10, Iss 4, Pp 526-527 https://doi.org/10.1590/S1679-45082012000400024 kostenfrei https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en kostenfrei https://doaj.org/toc/1679-4508 Journal toc kostenfrei https://doaj.org/toc/2317-6385 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR São Paulo, Vol 10, Iss 4, Pp 526-527 |
| spelling |
10.1590/S1679-45082012000400024 doi (DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 DE-627 ger DE-627 rakwb eng por Carlos Eduardo dos Santos Ferreira verfasserin aut PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia São Paulo, Vol 10, Iss 4, Pp 526-527 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. dislipidemias lipoproteínas ldl-colesterol Medicine R Francisco Antônio Helfenstein Fonseca verfasserin aut Cristóvão Luis Pitangueira Mangueira verfasserin aut In Einstein (São Paulo) Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 (São Paulo, Vol 10, Iss 4, Pp 526-527) (DE-627)561316503 (DE-600)2418293-X 23176385 nnns year:São Paulo, Vol 10, Iss 4, Pp 526-527 https://doi.org/10.1590/S1679-45082012000400024 kostenfrei https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en kostenfrei https://doaj.org/toc/1679-4508 Journal toc kostenfrei https://doaj.org/toc/2317-6385 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR São Paulo, Vol 10, Iss 4, Pp 526-527 |
| allfields_unstemmed |
10.1590/S1679-45082012000400024 doi (DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 DE-627 ger DE-627 rakwb eng por Carlos Eduardo dos Santos Ferreira verfasserin aut PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia São Paulo, Vol 10, Iss 4, Pp 526-527 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. dislipidemias lipoproteínas ldl-colesterol Medicine R Francisco Antônio Helfenstein Fonseca verfasserin aut Cristóvão Luis Pitangueira Mangueira verfasserin aut In Einstein (São Paulo) Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 (São Paulo, Vol 10, Iss 4, Pp 526-527) (DE-627)561316503 (DE-600)2418293-X 23176385 nnns year:São Paulo, Vol 10, Iss 4, Pp 526-527 https://doi.org/10.1590/S1679-45082012000400024 kostenfrei https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en kostenfrei https://doaj.org/toc/1679-4508 Journal toc kostenfrei https://doaj.org/toc/2317-6385 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR São Paulo, Vol 10, Iss 4, Pp 526-527 |
| allfieldsGer |
10.1590/S1679-45082012000400024 doi (DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 DE-627 ger DE-627 rakwb eng por Carlos Eduardo dos Santos Ferreira verfasserin aut PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia São Paulo, Vol 10, Iss 4, Pp 526-527 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. dislipidemias lipoproteínas ldl-colesterol Medicine R Francisco Antônio Helfenstein Fonseca verfasserin aut Cristóvão Luis Pitangueira Mangueira verfasserin aut In Einstein (São Paulo) Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 (São Paulo, Vol 10, Iss 4, Pp 526-527) (DE-627)561316503 (DE-600)2418293-X 23176385 nnns year:São Paulo, Vol 10, Iss 4, Pp 526-527 https://doi.org/10.1590/S1679-45082012000400024 kostenfrei https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en kostenfrei https://doaj.org/toc/1679-4508 Journal toc kostenfrei https://doaj.org/toc/2317-6385 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR São Paulo, Vol 10, Iss 4, Pp 526-527 |
| allfieldsSound |
10.1590/S1679-45082012000400024 doi (DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 DE-627 ger DE-627 rakwb eng por Carlos Eduardo dos Santos Ferreira verfasserin aut PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia São Paulo, Vol 10, Iss 4, Pp 526-527 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. dislipidemias lipoproteínas ldl-colesterol Medicine R Francisco Antônio Helfenstein Fonseca verfasserin aut Cristóvão Luis Pitangueira Mangueira verfasserin aut In Einstein (São Paulo) Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017 (São Paulo, Vol 10, Iss 4, Pp 526-527) (DE-627)561316503 (DE-600)2418293-X 23176385 nnns year:São Paulo, Vol 10, Iss 4, Pp 526-527 https://doi.org/10.1590/S1679-45082012000400024 kostenfrei https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en kostenfrei https://doaj.org/toc/1679-4508 Journal toc kostenfrei https://doaj.org/toc/2317-6385 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR São Paulo, Vol 10, Iss 4, Pp 526-527 |
| language |
English Portuguese |
| source |
In Einstein (São Paulo) (São Paulo, Vol 10, Iss 4, Pp 526-527) year:São Paulo, Vol 10, Iss 4, Pp 526-527 |
| sourceStr |
In Einstein (São Paulo) (São Paulo, Vol 10, Iss 4, Pp 526-527) year:São Paulo, Vol 10, Iss 4, Pp 526-527 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
dislipidemias lipoproteínas ldl-colesterol Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Einstein (São Paulo) |
| authorswithroles_txt_mv |
Carlos Eduardo dos Santos Ferreira @@aut@@ Francisco Antônio Helfenstein Fonseca @@aut@@ Cristóvão Luis Pitangueira Mangueira @@aut@@ |
| publishDateDaySort_date |
0010-01-01T00:00:00Z |
| hierarchy_top_id |
561316503 |
| id |
DOAJ002336081 |
| language_de |
englisch portugiesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ002336081</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309170109.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1679-45082012000400024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ002336081</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Carlos Eduardo dos Santos Ferreira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dislipidemias</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipoproteínas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ldl-colesterol</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisco Antônio Helfenstein Fonseca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristóvão Luis Pitangueira Mangueira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Einstein (São Paulo)</subfield><subfield code="d">Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017</subfield><subfield code="g">(São Paulo, Vol 10, Iss 4, Pp 526-527)</subfield><subfield code="w">(DE-627)561316503</subfield><subfield code="w">(DE-600)2418293-X</subfield><subfield code="x">23176385</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1679-45082012000400024</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1679-4508</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2317-6385</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield></record></collection>
|
| author |
Carlos Eduardo dos Santos Ferreira |
| spellingShingle |
Carlos Eduardo dos Santos Ferreira misc dislipidemias misc lipoproteínas misc ldl-colesterol misc Medicine misc R PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| authorStr |
Carlos Eduardo dos Santos Ferreira |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)561316503 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
23176385 |
| topic_title |
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia dislipidemias lipoproteínas ldl-colesterol |
| topic |
misc dislipidemias misc lipoproteínas misc ldl-colesterol misc Medicine misc R |
| topic_unstemmed |
misc dislipidemias misc lipoproteínas misc ldl-colesterol misc Medicine misc R |
| topic_browse |
misc dislipidemias misc lipoproteínas misc ldl-colesterol misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Einstein (São Paulo) |
| hierarchy_parent_id |
561316503 |
| hierarchy_top_title |
Einstein (São Paulo) |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)561316503 (DE-600)2418293-X |
| title |
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| ctrlnum |
(DE-627)DOAJ002336081 (DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3 |
| title_full |
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| author_sort |
Carlos Eduardo dos Santos Ferreira |
| journal |
Einstein (São Paulo) |
| journalStr |
Einstein (São Paulo) |
| lang_code |
eng por |
| isOA_bool |
true |
| recordtype |
marc |
| contenttype_str_mv |
txt |
| author_browse |
Carlos Eduardo dos Santos Ferreira Francisco Antônio Helfenstein Fonseca Cristóvão Luis Pitangueira Mangueira |
| format_se |
Elektronische Aufsätze |
| author-letter |
Carlos Eduardo dos Santos Ferreira |
| doi_str_mv |
10.1590/S1679-45082012000400024 |
| author2-role |
verfasserin |
| title_sort |
pcsk9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| title_auth |
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| abstract |
This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. |
| abstractGer |
This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. |
| abstract_unstemmed |
This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia |
| url |
https://doi.org/10.1590/S1679-45082012000400024 https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en https://doaj.org/toc/1679-4508 https://doaj.org/toc/2317-6385 |
| remote_bool |
true |
| author2 |
Francisco Antônio Helfenstein Fonseca Cristóvão Luis Pitangueira Mangueira |
| author2Str |
Francisco Antônio Helfenstein Fonseca Cristóvão Luis Pitangueira Mangueira |
| ppnlink |
561316503 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1590/S1679-45082012000400024 |
| up_date |
2024-07-04T00:49:07.336Z |
| _version_ |
1803607497599090688 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ002336081</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309170109.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1679-45082012000400024</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ002336081</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ93ad9ab7be404629a2055e56fdfe21d3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Carlos Eduardo dos Santos Ferreira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dislipidemias</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipoproteínas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ldl-colesterol</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francisco Antônio Helfenstein Fonseca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristóvão Luis Pitangueira Mangueira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Einstein (São Paulo)</subfield><subfield code="d">Instituto Israelita de Ensino e Pesquisa Albert Einstein, 2017</subfield><subfield code="g">(São Paulo, Vol 10, Iss 4, Pp 526-527)</subfield><subfield code="w">(DE-627)561316503</subfield><subfield code="w">(DE-600)2418293-X</subfield><subfield code="x">23176385</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1679-45082012000400024</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/93ad9ab7be404629a2055e56fdfe21d3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082012000400024&lng=en&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1679-4508</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2317-6385</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">São Paulo, Vol 10, Iss 4, Pp 526-527</subfield></datafield></record></collection>
|
| score |
7.400464 |